Genprex (GNPX) warrant holders report 249,788 shares, 2.69% stake
Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B), and Waqas Khatri have reported beneficial ownership of 249,788 shares of Genprex, Inc. common stock, exercisable through warrants. This represents a 2.69% stake, based on 9,044,856 shares outstanding as of March 27, 2026, and is subject to a 9.99% beneficial ownership blocker. The filing is a routine disclosure of derivative-based ownership, as the holdings are under 5% and include an ownership cap.
MAY 6·Benzinga→
Top 3 Health Care Stocks That Are Set To Fly In Q2
This article highlights three oversold healthcare stocks – Medtronic (MDT), Option Care Health (OPCH), and Genprex (GNPX) – that could see upward movement in Q2, based on a Relative Strength Index (RSI) near or below 30. It details recent company news, stock performance, and RSI values for each, suggesting an opportunity for investors to consider undervalued companies. The piece utilizes Benzinga Pro data to identify these potential breakouts.
APR 29·Stock Titan▼
Genprex (NASDAQ: GNPX) seeks approval for equity plan and reverse stock split
Genprex (NASDAQ: GNPX) is seeking stockholder approval for several key proposals at its virtual annual meeting on June 18, 2026, including the election of two Class III directors, ratification of its independent auditor, and an advisory vote on executive compensation. Critically, the company also proposes to amend and restate its 2018 Equity Incentive Plan and authorize a reverse stock split at a ratio between 1-for-5 and 1-for-50, which the board could implement anytime before December 31, 2027. These capital structure changes aim to provide flexibility for future equity issuance and maintain NASDAQ listing compliance.
